Rationale for the prevention of disseminated Mycobacterium avium-intracellulare complex disease
1Service de Pneumologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Abstract:
The survival rate in patients with AIDS who have CD4+ cell counts < 75 cells/microliter is increasing because of improved preventive and treatment strategies for opportunistic infections and also because of the efficacy of antiretroviral drug treatment. These patients are at high risk of developing disseminated Mycobacterium avium-intracellulare (MAC) disease, which decreases both quality of life and life expectancy. Measures aimed at preventing MAC contamination are largely ineffective in decreasing the incidence of disseminated MAC disease in patients with AIDS, because of the large natural reservoir of MAC. Chemoprophylaxis is superior to early bacteriological diagnosis as a preventive strategy, and it is preferable to wait for the appearance of symptoms of disseminated MAC disease before a curative treatment is initiated. Well-conducted studies of clarithromycin or rifabutin monotherapy as chemoprophylaxis have demonstrated a decrease in the incidence of disseminated MAC disease, as well as an increase in quality of life and survival. Clarithromycin, azithromycin and rifabutin have all been shown to be effective as prophylaxis against disseminated MAC disease. Although some combinations of drugs have been shown to be more effective than monotherapy in preventing disseminated MAC disease, these regimens are more costly and have less favourable tolerability profiles than single-agent treatment. In conclusion, chemoprophylaxis is the most effective preventive strategy against disseminated MAC disease and has been shown to improve quality of life and to decrease the risk of death associated with this disease in AIDS patients.
Insights
Chemoprophylaxis significantly reduces Mycobacterium avium-intracellulare (MAC) disease incidence in AIDS patients. This preventive strategy improves quality of life and survival rates for individuals with advanced HIV infection.
Area of Science:
- Infectious Diseases
- Immunology
- Public Health
Background:
- Patients with Acquired Immunodeficiency Syndrome (AIDS) and low CD4+ counts face increased risk of disseminated Mycobacterium avium-intracellulare (MAC) disease.
- Disseminated MAC disease significantly impairs quality of life and reduces life expectancy in this vulnerable population.
- Preventive measures targeting MAC contamination are often ineffective due to MAC's extensive environmental presence.
Purpose of the Study:
- To evaluate the efficacy of chemoprophylaxis in preventing disseminated MAC disease in patients with AIDS.
- To compare chemoprophylaxis with early bacteriological diagnosis and symptomatic treatment initiation.
Main Methods:
- Review of well-conducted studies evaluating clarithromycin or rifabutin monotherapy for MAC chemoprophylaxis.
- Analysis of data on the effectiveness of clarithromycin, azithromycin, and rifabutin as prophylactic agents.
- Comparison of monotherapy versus combination drug regimens for MAC prevention.
Main Results:
- Chemoprophylaxis with clarithromycin or rifabutin monotherapy demonstrably decreases the incidence of disseminated MAC disease.
- Prophylactic treatment with clarithromycin, azithromycin, or rifabutin improves quality of life and survival outcomes.
- While combination therapies may offer higher efficacy, they present increased costs and reduced tolerability compared to single-agent treatments.
Conclusions:
- Chemoprophylaxis is the most effective strategy for preventing disseminated MAC disease in AIDS patients.
- Prophylactic treatment significantly enhances the quality of life and decreases mortality risk associated with MAC disease in this population.
Related Concept Videos
01:20Infection
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:27Cryptococcal Meningitis
01:25Clinical Significance of Antibiotic Resistance